GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice
A prespecified secondary analysis of SELECT participants without diabetes showed that semaglutide reduced the composite kidney endpoint by 22% (86), with 75% of participants on RAAS blocker therapy at baseline
It belongs to a novel class of agents known as triple receptor agonists, meaning it is designed to simultaneously activate three distinct hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor
The weight loss and A1c results are unprecedented
Like other popular GLP-1s, it helps you feel full so you naturally eat less
Results From 163 studies that met inclusion criteria, 23 PROMs were included in the readability analysis